Information Provided By:
Fly News Breaks for September 4, 2019
BHVN
Sep 4, 2019 | 10:17 EDT
Biohaven Pharmaceutical disclosed this morning that the new drug application filing for rimegepant ODT has been accepted with a Q1 of 2020 FDA action date, Goldman Sachs analyst Paul Choi tells investors in a research note. Recent discussions suggested investor worries about a potential refusal to file response on either data or safety, so this morning's update should be received positively, says the analyst. With the filing in hand, Choi thinks the recent pullback in Biohaven shares "creates an attractive entry ahead of several important near term catalysts." He keeps a Buy rating on Biohaven Pharmaceutical with an $89 price target. The stock in morning trading is up 7% to $40.77.
News For BHVN From the Last 2 Days
There are no results for your query BHVN